GlassScriptPhysician profile
Michelle T Dyer
NPI 1790079465
$32,948.07
in general payments reported to CMS, 2019-2025
27 companies · $17K in 2025
The $17K reported for 2025 was more than what 99% of Psychiatric/Mental Health (Nurse Practitioner) providers received nationally (typical 2025 total: $257).
See the full distribution for Psychiatric/Mental Health (Nurse Practitioner)
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $1,588 · 2022: $1,386 · 2023: $1,828 · 2024: $11K · 2025: $17K.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program: $20K · Food and Beverage: $7,582 · Travel and Lodging: $2,173 · Education: $59.63.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program | $20,160.00 |
| Food and Beverage | $7,581.53 |
| Travel and Lodging | $2,172.74 |
| Education | $59.63 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Janssen Pharmaceuticals, INC | $24,330.74 | 2021-2025 | Spravato, Invega Sustenna, Invega Trinza |
| Abbvie INC. | $2,058.39 | 2021-2025 | |
| Otsuka America Pharmaceutical, INC. | $1,190.99 | 2021-2025 | Rexulti, Abilify Maintena, Abilify Asimtufii |
| Neurocrine Biosciences, INC. | $908.97 | 2021-2025 | Ingrezza |
| Alkermes, INC. | $792.03 | 2021-2025 | Aristada, Lybalvi |
| Vanda Pharmaceuticals INC. | $621.18 | 2021-2025 | Fanapt, Hetlioz |
| Axsome Therapeutics, INC. | $504.02 | 2022-2025 | Auvelity |
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $484.34 | 2021-2025 | Caplyta |
| Teva Pharmaceuticals USA, INC. | $356.48 | 2022-2025 | Austedo Xr, Uzedy, Austedo Xr |
| Sunovion Pharmaceuticals INC. | $312.81 | 2021-2022 | |
| Idorsia Pharmaceuticals US INC | $256.03 | 2023-2025 | Quviviq, Quviviq |
| Corium, LLC | $210.56 | 2021-2025 | Azstarys |
| Takeda Pharmaceuticals U.S.A., INC. | $198.65 | 2021-2025 | Trintellix |
| Alexion Pharmaceuticals, INC. | $130.20 | 2023 | |
| Glaxosmithkline, LLC. | $112.95 | 2021 |
Show all 27 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Supernus Pharmaceuticals, INC. | $102.30 | 2023-2025 | Qelbree, Qelbree |
| Collegium Pharmaceutical, INC. | $99.87 | 2025 | Jornay Pm |
| Ironshore Pharmaceuticals INC. | $52.85 | 2023-2024 | Jornay Pm |
| Lundbeck LLC | $42.39 | 2022 | |
| Indivior INC. | $38.74 | 2022 | |
| Merck Sharp & Dohme LLC | $33.61 | 2021-2022 | |
| Bausch Health US, LLC | $29.52 | 2022-2023 | Aplenzin, Wellbutrin |
| Noven Therapeutics, LLC | $22.40 | 2025 | Secuado, Xelstrym |
| Neos Therapeutics, LP | $17.16 | 2025 | Adzenys Xr-Odt |
| Neuronetics, INC. | $15.71 | 2023 | Neurostar Tms Therapy System |
| Alfasigma USA, INC. | $13.81 | 2022 | |
| Eisai INC. | $11.37 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Michelle Dyer listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.